Literature DB >> 33755082

Screening for Hearing Loss in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Cynthia Feltner1,2,3, Ina F Wallace1,4, Christine E Kistler1,3,5, Manny Coker-Schwimmer1,3, Daniel E Jonas1,2,3.   

Abstract

Importance: Hearing loss is common in older adults and associated with adverse health and social outcomes. Objective: To update the evidence review on screening for hearing loss in adults 50 years or older to inform the US Preventive Services Task Force. Data Sources: MEDLINE, Cochrane Library, EMBASE, and trial registries through January 17, 2020; references; and experts; literature surveillance through October 8, 2020. Study Selection: English-language studies of accuracy, screening, and interventions for screen-detected or newly detected hearing loss. Data Extraction and Synthesis: Dual review of abstracts, full-text articles, and study quality. Meta-analysis of screening test accuracy studies. Main Outcomes and Measures: Quality of life and function, other health and social outcomes, test accuracy, and harms.
Results: Forty-one studies (N = 26 386) were included, 18 of which were new since the previous review. One trial enrolling US veterans (n = 2305) assessed the benefits of screening; there was no significant difference in the proportion of participants experiencing a minimum clinically important difference in hearing-related function at 1 year (36%-40% in the screened groups vs 36% in the nonscreened group). Thirty-four studies (n = 23 228) evaluated test accuracy. For detecting mild hearing loss (>20-25 dB), single-question screening had a pooled sensitivity of 66% (95% CI, 58%-73%) and a pooled specificity of 76% (95% CI, 68%-83%) (10 studies, n = 12 637); for detecting moderate hearing loss (>35-40 dB), pooled sensitivity was 80% (95% CI, 68%-88%) and pooled specificity was 74% (95% CI, 59%-85%) (6 studies, n = 8774). In 5 studies (n = 2820) on the Hearing Handicap Inventory for the Elderly-Screening to detect moderate hearing loss (>40 dB), pooled sensitivity was 68% (95% CI, 52%-81%) and pooled specificity was 78% (95% CI, 67%-86%). Six trials (n = 853) evaluated amplification vs control in populations with screen-detected or recently detected hearing loss over 6 weeks to 4 months. Five measured hearing-related function via the Hearing Handicap Inventory for the Elderly; only 3 that enrolled veterans (n = 684) found a significant difference considered to represent a minimal important difference (>18.7 points). Few trials reported on other eligible outcomes, and no studies reported on harms of screening or interventions. Conclusions and Relevance: Several screening tests can adequately detect hearing loss in older adults; no studies reported on the harms of screening or treatment. Evidence showing benefit from hearing aids on hearing-related function among adults with screen-detected or newly detected hearing loss is limited to studies enrolling veterans.

Entities:  

Mesh:

Year:  2021        PMID: 33755082     DOI: 10.1001/jama.2020.24855

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Validation of a tablet-based assessment of auditory sensitivity for researchers.

Authors:  Kathryn Wiseman; Jerry Slotkin; Meredith Spratford; Amberlee Haggerty; Maggie Heusinkvelt; Sandra Weintraub; Richard Gershon; Ryan McCreery
Journal:  Behav Res Methods       Date:  2022-08-12

2.  A pragmatic clinical trial of hearing screening in primary care clinics: cost-effectiveness of hearing screening.

Authors:  Judy R Dubno; Pranab Majumder; Janet Prvu Bettger; Rowena J Dolor; Victoria Eifert; Howard W Francis; Carl F Pieper; Kristine A Schulz; Mina Silberberg; Sherri L Smith; Amy R Walker; David L Witsell; Debara L Tucci
Journal:  Cost Eff Resour Alloc       Date:  2022-06-25

3.  Prevalence of Hearing Loss and Hearing Aid Use Among Adults in France in the CONSTANCES Study.

Authors:  Quentin Lisan; Marcel Goldberg; Ghizlene Lahlou; Anna Ozguler; Sylvie Lemonnier; Xavier Jouven; Marie Zins; Jean-Philippe Empana
Journal:  JAMA Netw Open       Date:  2022-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.